Study
| Phase 3, international, randomized trial (PAPILLON) |
| Advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy |
| Amivantamab + Chemoterapy (n=153) vs. Chemotherapy (n=155) |
Efficacy
| mPFS: 11.4 vs. 6.7 mos, HR:0.40, p<0.001 |
| 18 mos PFS: 31% vs. 3% |
| ORR: 73% vs. 47% |
| mDoR: 9.7 vs. 4.4 mos |
Safety
| • Grade3: Neutropenia (33% vs. 23%), anemia (11% vs. 12%), thrombocytopenia (10% vs. 10%), rash (11% vs. 0) |
N Engl J Med 2023 Oct 21
Zhou C Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
http://doi.org/10.1056/NEJMoa2306441
Reviewed by Ulas D. Bayraktar, MD on Jan 13, 2024
